Stuart Roberts News
-
When Gary Wittert began looking for tubby male baby boomers to take part in a clinical trial last month, he got 800 volunteers in one day. The draw: free testosterone injections.
-
Sigma Pharmaceuticals Ltd. , the unprofitable owner of the Guardian drugstore brand, received a A$707 million ($579 million) takeover proposal, 71 percent more than its market value.
-
Grifols SA , Europe’s largest maker of blood-plasma products, is in talks to buy Talecris Biotherapeutics Holdings Corp. for more than $3 billion, a person briefed on the discussions said.
-
Aspen Pharmacare Holdings Ltd. will reduce its A$707 million ($596 million) takeover offer for Sigma Pharmaceuticals Ltd. after reviewing the Australian company’s accounts, a person familiar with the matter said.
-
Patients with heart failure can reduce the risk of further occurrences by as much as 80 percent using an experimental stem-cell treatment, according to a study whose results are among the most promising for such therapies.
-
Grifols SA , Europe’s largest maker of blood-plasma products, agreed to buy Talecris Biotherapeutics Holdings Corp. for about $3 billion in cash and stock to expand its share to almost a third of the U.S. market.
-
QRxPharma Ltd., the Australian drugmaker seeking U.S. approval for a new pain treatment, is in talks with other companies to help market the medicine, Chief Executive Officer John Holaday said.
-
Cephalon Inc. took a 20 percent stake in Mesoblast Ltd. and bought the rights to market the Australian company’s adult stem-cell therapies for heart and nervous system conditions in a deal potentially worth more than $2 billion.
-
Sonic Healthcare Ltd. , Australia’s biggest provider of medical tests, said profit may rise less than previously forecast because of uncertain demand in the domestic market.
-
Talecris Biotherapeutics Holdings Corp. will proceed with an $800 million expansion of its blood- plasma production capacity amid an announced takeover by Grifols SA , Chief Executive Officer Lawrence Stern said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page